Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Royal Bank Of Canada

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by Royal Bank Of Canada from $126.00 to $131.00 in a research report released on Friday,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently weighed in on GILD. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. BMO Capital Markets reissued an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a report on Friday. HSBC raised their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Barclays decreased their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Finally, UBS Group reaffirmed a “buy” rating and set a $195.00 target price on shares of Gilead Sciences in a report on Friday. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $169.19.

Gilead Sciences Stock Performance

GILD stock opened at $170.68 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences has a 1-year low of $114.02 and a 1-year high of $175.65. The firm has a fifty day moving average price of $150.87 and a two-hundred day moving average price of $139.79.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the prior year, the company earned $2.47 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is -122.85%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer owned 577,133 shares in the company, valued at approximately $85,785,049.12. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 111,000 shares of company stock valued at $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently made changes to their positions in the business. Covestor Ltd boosted its position in Gilead Sciences by 21.5% during the 3rd quarter. Covestor Ltd now owns 876 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 155 shares during the period. Caldwell Trust Co grew its stake in shares of Gilead Sciences by 39.3% in the third quarter. Caldwell Trust Co now owns 1,705 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 481 shares in the last quarter. 3Chopt Investment Partners LLC grew its stake in shares of Gilead Sciences by 0.8% in the third quarter. 3Chopt Investment Partners LLC now owns 22,751 shares of the biopharmaceutical company’s stock worth $3,391,000 after purchasing an additional 180 shares in the last quarter. Rakuten Investment Management Inc. increased its holdings in shares of Gilead Sciences by 10.4% during the third quarter. Rakuten Investment Management Inc. now owns 330,225 shares of the biopharmaceutical company’s stock valued at $49,956,000 after purchasing an additional 31,109 shares during the period. Finally, Provenance Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 412.3% during the third quarter. Provenance Wealth Advisors LLC now owns 13,418 shares of the biopharmaceutical company’s stock valued at $2,000,000 after purchasing an additional 10,799 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.